Wells Fargo analyst Eva Fortea Verdejo raised the firm’s price target on Revolution Medicines (RVMD) to $144 from $100 and keeps an Overweight rating on the shares. The company is on track for their first pivotal readout in the first half of 2026 and the firm is confident on daraxon’s potential in second-line pancreatic ductal adenocarcinoma. Beyond RASolute 302, Wells is watching out for updated first-line data for daraxon and PDAC zoldon data.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RVMD:
- Revolution Medicines: Advancing RAS Inhibitor Pipeline and Strong Cash Runway Support Buy Rating
- Revolution Medicines reports Q4 EPS ($1.86), consensus ($1.56)
- Revolution Medicines sees FY26 operating expenses $1.6B-$1.7B
- Revolution Medicines initiated with an Outperform at Evercore ISI
- Is RVMD a Buy, Before Earnings?